First Time Loading...

SI-BONE Inc
NASDAQ:SIBN

Watchlist Manager
SI-BONE Inc Logo
SI-BONE Inc
NASDAQ:SIBN
Watchlist
Price: 15.82 USD 3.4% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

SIBN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. [ Read More ]

The intrinsic value of one SIBN stock under the Base Case scenario is 22.36 USD. Compared to the current market price of 15.82 USD, SI-BONE Inc is Undervalued by 29%.

Key Points:
SIBN Intrinsic Value
Base Case
22.36 USD
Undervaluation 29%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
SI-BONE Inc

Backtest SIBN Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling SIBN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

SI-BONE Grows Revenue by 31% in 2023
2023-Q4 Earnings Call

SI-BONE Grows Revenue by 31% in 2023

SI-BONE had an outstanding 2023, driven by strong U.S. demand, resulting in a record $138.9 million in worldwide revenue, a significant beat over the initial forecast of $124-$127 million, and marking a 31% year-over-year growth. U.S. physicians were key contributors, performing over 15,000 procedures. The company's focused investments in scalable operations led to a substantial 48% improvement in adjusted EBITDA. Continuing the positive trend, the annual procedure volume growth rate in the U.S. hit 25% and revenue per U.S. territory surged 39% to $1.6 million. With a thriving physician engagement, SI-BONE is now targeting nearly 0.5 million annual sacropelvic procedures as they plan for an eventful 2024 with new product launches and further market penetration.

Financials

Balance Sheet Decomposition
SI-BONE Inc

Current Assets 211.4m
Cash & Short-Term Investments 166m
Receivables 22m
Other Current Assets 23.4m
Non-Current Assets 19m
PP&E 18.7m
Other Non-Current Assets 325k
Current Liabilities 23.5m
Accounts Payable 4.6m
Accrued Liabilities 18.9m
Non-Current Liabilities 37.6m
Long-Term Debt 36.1m
Other Non-Current Liabilities 1.5m
Efficiency

Earnings Waterfall
SI-BONE Inc

Revenue
138.9m USD
Cost of Revenue
-29.5m USD
Gross Profit
109.4m USD
Operating Expenses
-156.4m USD
Operating Income
-46.9m USD
Other Expenses
3.6m USD
Net Income
-43.3m USD

Free Cash Flow Analysis
SI-BONE Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

SIBN Profitability Score
Profitability Due Diligence

SI-BONE Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROIC is Increasing
Exceptional 3-Years Revenue Growth
Positive Revenue Growth Forecast
30/100
Profitability
Score

SI-BONE Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

SIBN Solvency Score
Solvency Due Diligence

SI-BONE Inc's solvency score is 85/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Negative Net Debt
Long-Term Solvency
85/100
Solvency
Score

SI-BONE Inc's solvency score is 85/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SIBN Price Targets Summary
SI-BONE Inc

Wall Street analysts forecast SIBN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SIBN is 27.41 USD with a low forecast of 24.24 USD and a high forecast of 33.6 USD.

Lowest
Price Target
24.24 USD
53% Upside
Average
Price Target
27.41 USD
73% Upside
Highest
Price Target
33.6 USD
112% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

SIBN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

SIBN Price
SI-BONE Inc

1M 1M
-9%
6M 6M
-26%
1Y 1Y
-19%
3Y 3Y
-49%
5Y 5Y
-14%
10Y 10Y
-21%
Annual Price Range
15.82
52w Low
15.15
52w High
28.9
Price Metrics
Average Annual Return -2.55%
Standard Deviation of Annual Returns 35.73%
Max Drawdown -69%
Shares Statistics
Market Capitalization 640.7m USD
Shares Outstanding 41 064 500
Percentage of Shares Shorted 6.35%

SIBN Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

SI-BONE Inc Logo
SI-BONE Inc

Country

United States of America

Industry

Health Care

Market Cap

640.7m USD

Dividend Yield

0%

Description

SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. The company is headquartered in Santa Clara, California and currently employs 352 full-time employees. The company went IPO on 2018-10-17. The firm is focused on the development of implantable devices used in the surgical treatment of sacro-pelvic anatomy. Its invasive surgical implant system, iFuse, is used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. Its iFuse Implant System includes a series of triangular titanium implants and the instruments developed to enable surgeons to perform the procedure. Its iFuse system, which includes its implants and instruments, is designed to address the shortcomings of alternative treatments, including open surgery, non-surgical management, and screw-based and other minimally invasive stabilization and fusion procedures. Its iFuse-3D design allows the surgeons to fill the implant with ground-up bone before implantation, which accelerates bone through-growth and biological fixation. The company also provides other technologies for its surgeons other than iFuse and iFuse-3D.

Contact

CALIFORNIA
Santa Clara
471 El Camino Real Ste 101
+14082070700.0
https://si-bone.com/

IPO

2018-10-17

Employees

352

Officers

CEO & Director
Ms. Laura A. Francis MBA
Chief Financial Officer
Mr. Anshul Maheshwari
President of Commercial Operations
Mr. Anthony J. Recupero
Senior Vice President of Operations & Information Technology
Mr. Jeff Bertolini
Senior VP of Engineering & CTO
Dr. Scott A. Yerby
Chief Business & Legal Affairs Officer
Mr. Michael A. Pisetsky
Show More
Vice President of People & Culture
Ms. Aimee Einstein
Senior Vice President of Clinical & Regulatory Affairs
Dr. Daniel Joseph Cher
Chief Medical Officer & VP of Medical Affairs
Dr. W. Carlton Reckling
Senior Vice President of Product, Strategy & Business Development
Mr. Nikolas F. Kerr
Show Less

See Also

Discover More
What is the Intrinsic Value of one SIBN stock?

The intrinsic value of one SIBN stock under the Base Case scenario is 22.36 USD.

Is SIBN stock undervalued or overvalued?

Compared to the current market price of 15.82 USD, SI-BONE Inc is Undervalued by 29%.